Left atrial appendage occlusion

Series
Cardiovascular
Status
Published
Date
Number of report
070

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The following types of procedure will be considered:

  • percutaneous transluminal left atrial appendage occlusion;
  • thoracoscopic left atrial appendage closure.

The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of treatment of left appendage occlusion:

  • Abbott Laboratories (Amplatzer Amulet)
  • Aegis Medical (Sierra)
  • Atricure (AtriClip)
  • Biosense Webster (WaveCrest)
  • Boston Scientific (WATCHMAN)
  • Cardia (Ultrasept)
  • Lifetech Scientific (LAmbre)
  • Sentreheart (LARIAT)

Table of content is not available at the moment. Report is still ongoing.

17

Nov 2022

In November 2022, an annual update of the Swedish procedure coding system (Classification of Health Care Measures, KVÅ) was released to come into force from January 2023. A total of 119 new surgical procedure codes and 98 new medical procedure codes will be introduced concerning cardiovascular, diagnostic imaging, eHealth, endocrinology, endoscopy, ENT, gastrointestinal, IVD, nephrology and urology, peripheral vascular, and others.

Read more

15

Jul 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With regional decree 10778 of June 01, 2022, Tuscany Regional Healthcare has published assessments of nine medical devices in various therapeutic areas, such as cardiovascular and peripheral vascular areas, surgical procedures, orthopedics, and dermatology.

Read more

06

May 2022

In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.

Read more

08

Jul 2020

On June 18, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced four medical procedures which received a subsidy under the new innovative payment scheme: FFRct technique in the diagnosis of patients with chest pain; oral esketamine in patients with severe, non-psychotic, treatment-resistant depression; left atrial appendage closure in patients with atrial fibrillation and endolymphatic duct blockage in patients with uncontrollable Meniere's disease.

Read more

02

Apr 2020

In February 2020, the Andalusian Health Technology Assessment Department published an assessment report on the evaluation of effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation. The scientific evidence about the effectiveness and safety of the left atrial appendage closure through minimally invasive epicardial clipping is inadequate and insufficient; further research is needed.

Read more
(we accept only company emails)